World Investment Advisors Makes New $166,000 Investment in SELLAS Life Sciences Group, Inc. $SLS

Posted by Brenda Bartman on Jun 28th, 2026

World Investment Advisors acquired a new stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 44,123 shares of the company’s stock, valued at approximately $166,000.

A number of other institutional investors and hedge funds have also made changes to their positions in SLS. Grange Capital LLC lifted its position in shares of SELLAS Life Sciences Group by 18.5% during the 4th quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock valued at $60,000 after buying an additional 2,500 shares in the last quarter. Invesco Ltd. raised its position in SELLAS Life Sciences Group by 6.2% during the fourth quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after acquiring an additional 3,114 shares during the period. The Manufacturers Life Insurance Company raised its position in SELLAS Life Sciences Group by 13.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock worth $143,000 after acquiring an additional 4,564 shares during the period. Equitable Holdings Inc. lifted its holdings in SELLAS Life Sciences Group by 18.5% during the fourth quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock valued at $121,000 after purchasing an additional 5,000 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in SELLAS Life Sciences Group by 31.5% during the fourth quarter. ProShare Advisors LLC now owns 22,638 shares of the company’s stock valued at $85,000 after purchasing an additional 5,417 shares in the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Stock Performance

NASDAQ SLS opened at $12.39 on Friday. The business has a fifty day moving average price of $7.14 and a 200 day moving average price of $5.16. The company has a market cap of $2.44 billion, a P/E ratio of -53.87 and a beta of 2.50. SELLAS Life Sciences Group, Inc. has a one year low of $1.39 and a one year high of $12.43.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Maxim Group raised their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

Get Our Latest Stock Analysis on SELLAS Life Sciences Group

SELLAS Life Sciences Group Company Profile

(Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.